|
1
|
Field JK and Duffy SW: Lung cancer
screening: The way forward. Br J Cancer. 99:557–562. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu JJ, Rouse C, Xu X, Wang J, Onaitis MW
and Pendergast AM: Inactivation of ABL kinases suppress non-small
cell lung cancer metastasis. JCI Insight. 1:e896472016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poomakkoth N, Issa A, Abdulrahman N,
Abelaziz SG and Mraiche F: p90 ribosomal S6 kinase: A potential
therapeutic target in lung cancer. J Transl Med. 14:142016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li T, Kung HJ, Mack PC and Gandara DR:
Genotyping and genomic profiling of non-small-cell lung cancer:
Implications for current and future therapies. J Clin Oncol.
31:1039–1049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gridelli C, Bareschino MA, Schettino C,
Rossi A, Maione P and Ciardiello F: Erlotinib in non-small cell
lung cancer treatment: Current status and future development.
Oncologist. 12:840–849. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olaru OT, Nitulescu GM, Ortan A and
Dinu-Pirvu CE: Ethnomedicinal, Phytochemical and Pharmacological
profile of Anthriscus sylvestris as an alternative source for
anticancer lignans. Molecules. 20:15003–15022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kozawa M, Baba K, Matsuyama Y, Kido T,
Sakai M and Takemoto T: Components of the root of Anthriscus
sylvestris Hoffm. II. Insecticidal activity. Chem Pharm Bull.
30:2885–2888. 1982. View Article : Google Scholar
|
|
8
|
Kozawa M, Morita N and Hata K: Chemical
components of the roots of Anthriscus sylvestris Hoffm. L.
structures of an acyloxycarboxylic acid and a new
phenylpropanoidester, anthriscusin (authour's transl). Yakugaku
Zasshi. 98:1486–1490. 1978.(In Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurihara T, Kikuchi M, Suzuki S and
Hisamichi S: Studies on the constituents of Anthriscus sylvestris
Hoffm. L. On the components of the radix (authour's transl)
Yakugaku Zasshi. 98:1586–1597. 1978.(In Japanese). View Article : Google Scholar
|
|
10
|
Lim YH, Leem MJ, Shin DH, Chang HB, Hong
SW, Moon EY, Lee DK, Yoon SJ and Woo WS: Cytotoxic constituents
from the roots of Anthriscus sylvestris. Arch Pharm Res.
22:208–212. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin M, Moon TC, Quan Z, Lee E, Kim YK,
Yang JH, Suh SJ, Jeong TC, Lee SH, Kim CH and Chang HW: The
naturally occurring flavolignan, deoxypodophyllotoxin, inhibits
lipopolysaccharide-induced iNOS expression through the NF-kappaB
activation in RAW264.7 macrophage cells. Biol Pharm Bull.
31:1312–1315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kiso Y, Konno C, Hikino H, Yagi Y and
Hashimoto I: Liver-protective actions of desoxypodophyllotoxin and
its analogs. J Pharmacobiodyn. 5:638–641. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin SY, Yong YJ, Kim CG, Lee YH and Lim
Y: Deoxypodophyllotoxin induces G2/M cell cycle arrest and
apoptosis in HeLa cells. Cancer Letter. 287:231–239. 2010.
View Article : Google Scholar
|
|
14
|
Jiang Z, Wu M, Miao J, Duan H, Zhang S,
Chen M, Sun L, Wang Y, Zhang X, Zhu X and Zhang L:
Deoxypodophyllotoxin exerts both anti-angiogenic and vascular
disrupting effects. Int J Biochem Cell Biol. 45:1710–1719. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jung CH, Kim HM, Ahn JY, Jung SK, Um MY,
Son KH, Kim TW and Ha TY: Anthricin isolated from Anthriscus
sylvestris (L.) Hoffm. inhibits the growth of breast cancer
cells by inhibiting Akt/mTOR signaling, and its apoptotic effects
are enhanced by autophagy inhibition. Evid Based Complement
Alternat Med. 2013:3852192013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laron Z: Insulin-like growth factor 1
(IGF-1): A growth hormone. Mol Pathol. 54:311–316. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iams WT and Lovly CM: Molecular pathways:
Clinical applications and future direction of insulin-like growth
factor-1 receptor pathway blockade. Clin Cancer Res. 21:4270–4277.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
King H, Aleksic T, Haluska P and Macaulay
VM: Can we unlock the potential of IGF-1R inhibition in cancer
therapy? Cancer Treat Rev. 40:1096–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park E, Park SY, Kim H, Sun PL, Jin Y, Cho
SK, Kim K, Lee CT and Chung JH: Membranous insulin-like growth
factor-1 receptor (IGF1R) expression is predictive of poor
prognosis in patients with epidermal growth factor receptor
(EGFR)-mutant lung adenocarcinoma. J Pathol Transl Med. 49:382–388.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
National Research Council: Guide for the
care and use of laboratory animals. National Academies Press;
Eight: Washington DC: 2011
|
|
22
|
Geran RI, Greenberg NH, McDonald MM,
Schumacher A and Abbott BJ: Protocols for screening chemical agents
and natural products against animal tumours and other biological
system. Cancer Chemother Rep. 3:51–61. 1972.
|
|
23
|
Bertrand FE, Steelman LS, Chappell WH,
Abrams SL, Shelton JG, White ER, Ludwig DL and McCubrey JA: Synergy
between an IGF 1R antibody and Raf//MEK//ERK and PI3K//Akt//mTOR
pathway inhibitors in suppressing IGF 1R mediated growth in
hematopoietic cells. Leukemia. 20:1254–1260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang YR, Xu Y, Jiang ZZ, Guerram M, Wang
B, Zhu X and Zhang LY: Deoxypodophyllotoxin induces G2/M cell cycle
arrest and apoptosis in SGC-7901 cells and inhibits tumor growth in
vivo. Molecules. 20:1661–1675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu M, Jiang Z, Duan H, Sun L, Zhang S,
Chen M, Wang Y, Gao Q, Song Y, Zhu X and Zhang L:
Deoxypodophyllotoxin triggers necroptosis in human non-small cell
lung cancer NCL-J460 cells. Biomed Pharmacother. 67:701–706. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
27
|
Wang Y and Sun Y: Insulin-like growth
factor receptor-1 as an anti-cancer target: Blocking transformation
and inducing apoptosis. Curr Cancer Drug Targets. 2:191–207. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hewish M, Chau I and Cunningham D:
Insulin-like growth factor 1 receptor targeted therapeutics: Novel
compounds and novel treatment strategies for cancer medicine.
Recent Pat Anticancer Drug Discov. 4:54–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeo CD, Park KH, Park CK, Lee SH, Kim SJ,
Yoon HK, Lee YS, Lee EJ, Lee KY and Kim TJ: Expression of
insulin-like growth factor 1 receptor (IGF-1R) predicts poor
responses to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors in non-small cell lung cancer patients harboring
activating EGFR mutations. Lung Cancer. 87:311–317. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van der Wekken AJ, Saber A, Hiltermann TJ,
Kok K, van den Berg A and Groen HJ: Resistance mechanisms after
tyrosine kinase inhibitors afatinib and crizotinib in non-small
cell lung cancer, a review of the literature. Crit Re Oncol
Hematol. 100:107–116. 2016. View Article : Google Scholar
|
|
31
|
Singh SS, Yap WN, Arfuso F, Kar S, Wang C,
Cai W, Dharmarajan AM, Sethi G and Kumar AP: Targeting the PI3K/Akt
signaling pathway in gastric carcinoma: A reality for personalized
medicine? World J Gastroenterol. 21:12261–12273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu S, Zhou Q, Wu WR, Duan YX, Gao ZY, Li
YW and Lu Q: Anticancer effect of deoxypodophyllotoxin induces
apoptosis of human prostate cancer cells. Oncol Lett. 12:2918–2923.
2016. View Article : Google Scholar : PubMed/NCBI
|
